Use of a disease risk score to compare serious infections associated with anti–tumor necrosis factor therapy among high‐ versus lower‐risk rheumatoid arthritis patients
Open Access
- 25 July 2012
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 64 (10), 1480-1489
- https://doi.org/10.1002/acr.21805
Abstract
Objective To evaluate whether rates of serious infection with anti–tumor necrosis factor (anti‐TNF) therapy in rheumatoid arthritis (RA) patients differ in magnitude by specific drugs and patient characteristics. Methods Among new nonbiologic disease‐modifying antirheumatic drug users enrolled in Medicare and Medicaid or a large US commercial health plan, we created and validated a person‐specific infection risk score based on age, demographics, insurance type, glucocorticoid dose, and comorbidities to identify patients at high risk for hospitalized infections. We then applied this risk score to new users of infliximab, etanercept, and adalimumab and compared the observed 1‐year rates of infection to one another and to the predicted infection risk score estimated in the absence of anti‐TNF exposure. Results Among 11,657 RA patients initiating anti‐TNF therapy, the observed 1‐year rate of infection was 14.2 infections per 100 person‐years in older patients (age ≥65 years) and 4.8 in younger patients (age <65 years). There was a relatively constant rate difference of ∼1–4 infections per 100 person‐years associated with anti‐TNF therapy across the range of the infection risk score. Infliximab had a significantly greater adjusted rate of infection compared to etanercept and adalimumab in both high‐ and lower‐risk RA patients. Conclusion The rate of serious infections for anti‐TNF agents was incrementally increased by a fixed absolute difference irrespective of age, comorbidities, and other factors that contributed to infections. Older patients and those with high comorbidity burdens should be reassured that the magnitude of their incremental risk with anti‐TNF agents is not greater than for lower‐risk patients.Keywords
This publication has 52 references indexed in Scilit:
- Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune DiseasesJama-Journal Of The American Medical Association, 2011
- Use of disease‐modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care SurveyArthritis Care & Research, 2011
- Study design for a comprehensive assessment of biologic safety using multiple healthcare data systemsPharmacoepidemiology and Drug Safety, 2011
- Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care PlansPublished by American Medical Association (AMA) ,2011
- Confounder summary scores when comparing the effects of multiple drug exposuresPharmacoepidemiology and Drug Safety, 2009
- Administrative codes combined with medical records based criteria accurately identified bacterial infections among rheumatoid arthritis patientsJournal of Clinical Epidemiology, 2009
- Drug‐specific and time‐dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor α antagonistsArthritis & Rheumatism, 2007
- Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studiesArthritis & Rheumatism, 2007
- A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methodsJournal of Clinical Epidemiology, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006